|
|
Mastering Treatment-Refractory nAMD
In this Master Class case, Dr. Michael Singer discusses the management of an 82-year-old Hispanic man with treatment-refractory neovascular age-related macular degeneration. |
|
|
Mastering Treatment-Refractory DME
In this Master Class case, Dr. Diana Do discusses the management of a 58-year-old White woman with treatment-refractory diabetic macular edema. |
|
|
Podcast: Multidisciplinary Task Force and Position Statement: Mitigating Disease Burden and Health Care Disparities in Relapsed/Refractory Multiple Myeloma
STATEMENT OF NEED
With the complex and rapidly evolving treatment landscape of multiple myeloma, it is vital that clinicians not only understand factors for informing selection of current and emerging combination and sequential therapeutic strategies, but also employ interdisciplinary strategies for reducing disparities in relapsed/refractory multiple myeloma care. The development of novel therapeutic options has significantly improved treatment outcomes for patients with relapsed/refractor... |
|
|
Treating SCLC in the Relapsed/Refractory Setting: Giving Patients a Voice About Second-Line Therapy
SCLC is aggressive in nature with a high recurrence rate following initial treatment and a propensity to become resistant to conventional therapies. Early detection is critical, but many patients are diagnosed at an advanced stage where prognosis is poor. Progress in the second-line setting offers new hope for improving patient outcomes, but the rapid pace at which these advances are occurring present challenges for effectively integrating novel therapies into patient care. In fact, research s... |
|
|
Opportunities with Novel Therapies to Treat the Entire Spectrum of Schizophrenia Symptoms
Available antipsychotic therapies for schizophrenia are effective in treating positive symptoms of schizophrenia yet significant unmet needs remain, including therapies that (1) are more effective in reducing negative and cognitive symptoms of schizophrenia; 2) have improved tolerability and adherence rates; and (3) that are effective in treating refractory schizophrenia. Fortunately, the schizophrenia treatment landscape is poised to change dramatically, offering new opportunities for patient... |
|
|
Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC.
Target Audience
The primary target audience for this activity are Academic and community-based physicians and team members, including hematologists, hematologic oncologists, medical oncologists, oncology nurses, NPs, PAs, and hematology-oncology pharmacists.
Statement of Need/Program Overview
Bispecific antibodies are relatively new agents in the treatment of multiple myeloma (MM). Because of this, many oncology clinicians are unfamiliar with their mechanism of action and the adverse even... |
|
|
Beyond the Guidelines for CMV: Clinical Perspectives on Challenging Cases Post-Transplant: A Clinical Forum®
Target Audience
Infectious disease, transplantation, internal medicine, and nephrology clinicians
Program Overview
Cytomegalovirus (CMV) is a prevalent and potentially life-threatening viral infection in transplant recipients. CMV management in this high-risk population continues to evolve with updated guidelines and newer, less toxic antiviral therapy.
During this activity, faculty will discuss state-of-the-art strategies for preventing and treating CMV in transplant patients, sharing... |
|